Phase I/II Study of TPF as First-line Chemotherapy in Patients With Metastatic Esophageal Cancer.
Status:
Completed
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
A phase I/II study is conducted to determine the maximum-tolerated dose (MTD), dose-limiting
toxicity (DLT), and efficacy of a combination chemotherapy using docetaxel, cisplatin and
5-fluorouracil (TPF) in untreated patients with metastatic esophageal cancer. The usefulness
of the this regimen is evaluated by response rate, median survival time, and progression free
survival.